Nithsdale Schizophrenia Surveys 24: sexual dysfunction

Macdonald, Shiona; Halliday, Jennifer; MacEwan, Tom; Sharkey, Val; Farrington, Susan M.; Wall, Stephanie; McCreadie, Robin G.

doi:10.1192/bjp.182.1.50

Cited by 153 publications

(120 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although 5AR inhibitors have been generally shown to have few untoward effects and to be well tolerated by patient, they have been shown to sporadically induce erectile dysfunction and gynecomastia (Wilton et al, 1996), which may in turn limit the medication compliance. Nevertheless, it is important to emphasize that these side effects are reportedly rare (Wilton et al, 1996;Wessells et al, 2003) and are also triggered by antipsychotic agents (Segraves, 1989;Macdonald et al, 2003).…”

Section: -A-reductase Inhibitors In Models Of Psychosis M Bortolato mentioning

confidence: 99%

Antipsychotic-Like Properties of 5-α-Reductase Inhibitors

Bortolato

Frau

Orrù

et al. 2008

Neuropsychopharmacol

View full text Add to dashboard Cite

Recent evidence indicates that neuroactive steroids may participate in the pathogenesis of schizophrenia spectrum disorders, yet the mechanisms of this involvement are elusive. As 5-a-reductase (5AR) is the rate-limiting enzyme of one of the two major metabolic pathways in brain steroidogenesis, we investigated the effects of its blockade in several rat models of psychotic-like behavior. The 5AR inhibitor finasteride (FIN, 60 or 100 mg/kg, intraperitoneal, i.p.) dose-and time-dependently antagonized prepulse inhibition (PPI) deficits induced by apomorphine (APO, 0.25 mg/kg, subcutaneous, s.c.) and d-amphetamine (AMPH, 5 mg/kg, s.c.), in a manner analogous to haloperidol (HAL, 0.1 mg/kg, i.p.) and clozapine (CLO, 5 mg/kg, i.p.). Similar results were observed with the other 5AR inhibitors dutasteride (DUT, 40 or 80 mg/kg, i.p.) and SKF 105111 (30 mg/kg, i.p.). FIN (60 or 100 mg/kg, i.p.) also reduced hyperlocomotion induced by AMPH (1 or 3 mg/kg, s.c.) and attenuated stereotyped behaviors induced by APO (0.25 mg/kg, s.c.). Nevertheless, FIN (100 mg/kg, i.p.) did not reverse the PPI disruption induced by the N-methyl-d-aspartate receptor antagonist dizocilpine (0.1 mg/kg, s.c.). FIN (60-300 mg/kg, i.p.) induced no catalepsy in either the bar test or the paw test. Our results suggest that 5AR inhibitors elicit antipsychotic-like effects in animals and may be proposed as a putative novel target in the management of psychotic disorders.

show abstract

Section: -A-reductase Inhibitors In Models Of Psychosis M Bortolato mentioning

confidence: 99%

Antipsychotic-Like Properties of 5-α-Reductase Inhibitors

Bortolato

Frau

Orrù

et al. 2008

Neuropsychopharmacol

View full text Add to dashboard Cite

show abstract

“…Common shortcomings of existing studies are the lack of a control group or the neglect of gender-specific aspects [4]. An issue of particular concern, however, is the reliability of the assessment instrument since low reliability impairs the power and the validity of a study [7].…”

Section: Discussionmentioning

confidence: 99%

“…Macdonald et al [4] comparing sexual functioning between schizophrenic patients and a population-based sample presented a self-completed genderspecific ''Sexual Behaviour Questionnaire'' (SBQ) covering desire, arousal, performance, and satisfaction. It showed striking face-validity and high clinical utility.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Development and Retest Reliability of a German Version of the Sexual Behaviour Questionnaire (SBQ-G)

Müller

2007

Archives of Andrology

View full text Add to dashboard Cite

A German version of the Sexual Behaviour Questionnaire (SBQ-G) is a short self-rating instrument covering the four domains of sexual function using colloquial words. Frequency of sexual dysfunction was counted and chance-corrected retest reliability was calculated. Eleven women and 12 men participated. Reception of the SBQ-G was favourable and more females than males reported at least moderate sexual dysfunction. Sexual arousal and ability to enjoy sex showed the lowest retest stability. The SBQ-G is a recommendable clinical instrument with high practicability and satisfactory retest reliability. However, gender differences and a high variability of sexual functioning in healthy subjects should be kept in mind.

show abstract

“…(Shader and Grinspoon, 1967). A recent survey showed that at least one symptom of sexual dysfunction was reported by 82% of men and 96% of women who had a diagnosis of schizophrenia (MacDonald, 2003).…”

Section: Introductionmentioning

confidence: 99%

Hyperprolactinaemia and Antipsychotic Drug Use : The Benefits of Prolactin Screening for Mental Health Patients

Shaw¹

2006

MHLDRP

View full text Add to dashboard Cite

Abstract:Hyperprolactinaemia is associated with drugs used in the field of Mental Health to treat psychosis (antipsychotic).This has been found to be affecting a significant number of service users taking this medication. Hyperprolactinaemia causes endocrine disturbances including sexual dysfunction and amenorrhea and infertility. However, in the longer term service users are at risk of some disabling conditions such as osteoporosis.As part of our ongoing medication management work, early detection of hyperprolactinaemia enables safer use of antipsychotic drugs.

show abstract

Nithsdale Schizophrenia Surveys 24: sexual dysfunction

Abstract: People with schizophrenia report much higher rates of sexual dysfunction than do the general population. Men and women with schizophrenia have a different pattern of sexual dysfunction.

Cited by 153 publications

References 16 publications

Antipsychotic-Like Properties of 5-α-Reductase Inhibitors

Antipsychotic-Like Properties of 5-α-Reductase Inhibitors

Development and Retest Reliability of a German Version of the Sexual Behaviour Questionnaire (SBQ-G)

Hyperprolactinaemia and Antipsychotic Drug Use : The Benefits of Prolactin Screening for Mental Health Patients

Contact Info

Product

Resources

About